Skip to main content

Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation

Review of the Literature and Clinical Suggestions

CNS Drugs volume 24, pages 193–206 (2010)Cite this article

Abstract

Individuals receiving certain atypical antipsychotic medications are at risk of gaining weight and developing metabolic problems. There are no established drug treatments to prevent or counter these problems. However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation. These studies suggest that metformin is beneficial if started early in antipsychotic drug treatment. Metformin has also been shown to prevent or delay the onset of type 2 diabetes mellitus in high-risk individuals from the general population. Based on these findings, we identify antipsychotic drug-treated patients who might benefit from metformin therapy and offer clinical guidelines for its use. Further long-term studies are needed to extend our observations and improve this strategy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Table I
Fig 1
Table II
Table III

References

  1. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005 Nov; 19(6 Suppl.): 16–27

    PubMed  Article  Google Scholar 

  2. Hasnain M, Vieweg WV, Fredrickson SK, et al. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009 Feb; 3(1): 5–15

    PubMed  Article  Google Scholar 

  3. Newcomer JW, Haupt DW. The metabolic effects of anti-psychotic medications. Can J Psychiatry 2006 Jul; 51(8): 480–91

    PubMed  Google Scholar 

  4. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 Jul; 93(1–3): 117–30

    PubMed  Article  Google Scholar 

  5. Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf 2007 Nov; 6(6): 651–62

    PubMed  Article  CAS  Google Scholar 

  6. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005 Dec; 150(6): 1115–21

    PubMed  Article  Google Scholar 

  7. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006 Jul; 14(4): 212–22

    PubMed  Article  Google Scholar 

  8. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004 Nov; 61(11): 1107–15

    PubMed  Article  Google Scholar 

  9. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 2005 Dec; 20Suppl. 4: S335–9

    PubMed  Article  Google Scholar 

  10. Gough SC, O’Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005 Nov; 19(6 Suppl.): 47–55

    PubMed  Article  Google Scholar 

  11. Tsang TM, Huang JT, Holmes E, et al. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 2006 Apr; 5(4): 756–60

    PubMed  Article  CAS  Google Scholar 

  12. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on anti-psychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601

    Article  Google Scholar 

  13. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry 2007; 68Suppl. 6: 14–23

    CAS  Google Scholar 

  14. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 Feb; 166(2): 152–63

    PubMed  Article  Google Scholar 

  15. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan 3; 373(9657): 31–41

    PubMed  Article  CAS  Google Scholar 

  16. Baptista T, ElFakih Y, Uzcategui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008; 22(6): 477–95

    PubMed  Article  CAS  Google Scholar 

  17. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006 Jul; 51(8): 502–11

    PubMed  Google Scholar 

  18. Top 200 generic drugs by units in 2007 [online]. Available from URL: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072008/491181/article.pdf [Accessed 2009 Jan 10]

  19. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7; 346(6): 393–403

    PubMed  Article  CAS  Google Scholar 

  20. Ratner RE. An update on the Diabetes Prevention Program. Endocr Pract 2006 Jan; 12Suppl. 1: 20–4

    PubMed  Google Scholar 

  21. Ramachandran A, Snehalatha C, Mary S, et al., Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006 Feb; 49(2): 289–97

    PubMed  Article  CAS  Google Scholar 

  22. Lebinger TG. Metformin and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2007 Apr; 14(2): 132–40

    PubMed  Article  CAS  Google Scholar 

  23. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008 May; 93(5): 1841–5

    PubMed  Article  CAS  Google Scholar 

  24. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999 Jul; 100(1): 3–16

    PubMed  Article  CAS  Google Scholar 

  25. Arman S, Sadramely MR, Nadi M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperi-done in children and adolescents. Saudi Med J 2008 Aug; 29(8): 1130–4

    PubMed  Google Scholar 

  26. Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001 Aug; 62(8): 653–5

    PubMed  Article  CAS  Google Scholar 

  27. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006 Mar; 51(3): 192–6

    PubMed  Google Scholar 

  28. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multi-centric, double-blind, placebo-controlled trial. Schizophr Res 2007 Jul; 93(1–3): 99–108

    PubMed  Article  Google Scholar 

  29. Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008 May 30; 159(1–2): 250–3

    PubMed  Article  CAS  Google Scholar 

  30. Chen CH, Chiu CC, Huang MC, et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008 May 15; 32(4): 925–31

    PubMed  Article  CAS  Google Scholar 

  31. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006 Dec; 163(12): 2072–9

    PubMed  Article  Google Scholar 

  32. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002 Apr; 159(4): 655–7

    PubMed  Article  Google Scholar 

  33. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008 Jan 9; 299(2): 185–93

    PubMed  Article  CAS  Google Scholar 

  34. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008 Mar; 165(3): 352–8

    PubMed  Article  Google Scholar 

  35. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 Jun 16; 269(23): 3015–23

  36. West DS, Elaine PT, Bursac Z, et al. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring) 2008 Jun; 16(6): 1413–20

    Article  Google Scholar 

  37. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006 Oct;61(10): 1075–81

    PubMed  Article  Google Scholar 

  38. Levri KM, Slaymaker E, Last A, et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 2005 Sep; 3(5): 457–61

    PubMed  Article  Google Scholar 

  39. Salpeter SR, Buckley NS, Kahn JA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008 Feb; 121(2): 149–57

    PubMed  Article  CAS  Google Scholar 

  40. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008 Apr; 21(4): 339–48

    PubMed  Article  CAS  Google Scholar 

  41. Trolle B, Flyvbjerg A, Kesmodel U, et al. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007 Nov; 22(11): 2967–73

    PubMed  Article  CAS  Google Scholar 

  42. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999 Apr; 22(4): 623–34

    Article  Google Scholar 

  43. Holt RI, Peveler RC. Antipsychotic drugs and diabetes: an application of the Austin Bradford Hill criteria. Diabetologia 2006 Jul; 49(7): 1467–76

    PubMed  Article  CAS  Google Scholar 

  44. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008 Apr; 28(2): 132–7

    PubMed  Article  CAS  Google Scholar 

  45. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007 May; 92(1–3): 95–102

    PubMed  Article  Google Scholar 

  46. Cohen D, Stolk RP, Grobbee DE, et al. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006 Apr; 29(4): 786–91

    PubMed  Article  Google Scholar 

  47. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002 Apr; 159(4): 561–6

    PubMed  Article  Google Scholar 

  48. Hammerman A, Dreiher J, Klang SH, et al. Antipsychotics and diabetes: an age-related association. Ann Pharmacother 2008 Sep; 42(9): 1316–22

    PubMed  Article  Google Scholar 

  49. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13(1): 27–35

    PubMed  Article  CAS  Google Scholar 

  50. Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007 Feb 27; 104(9): 3456–9

    PubMed  Article  CAS  Google Scholar 

  51. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain: mechanisms and genetics. J Psychopharmacol 2006 Jul; 20(4 Suppl.): 15–8

    PubMed  Article  Google Scholar 

  52. Sentissi O, Epelbaum J, Olie JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008 Nov; 34(6): 1189–99

    PubMed  Article  Google Scholar 

  53. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005 Oct; 20(5): 368–78

    PubMed  Article  CAS  Google Scholar 

  54. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 Jan; 62(1): 19–28

    PubMed  Article  CAS  Google Scholar 

  55. Murashita M, Kusumi I, Hosoda H, et al. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007 Aug; 32(7): 777–84

    PubMed  Article  CAS  Google Scholar 

  56. Tulipano G, Rizzetti C, Bianchi I, et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 2007; 85(2): 61–70

    PubMed  Article  CAS  Google Scholar 

  57. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007 Feb; 32(2): 289–97

    PubMed  Article  CAS  Google Scholar 

  58. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008 Jun; 33(7): 1633–41

    PubMed  Article  CAS  Google Scholar 

  59. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003 Dec; 88(12): 5875–80

    PubMed  Article  CAS  Google Scholar 

  60. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002 Jun; 87(6): 2918–23

    PubMed  Article  CAS  Google Scholar 

  61. Yasui-Furukori N, Sato Y, Furukori H, et al. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 2009 Jan; 70(1): 95–100

    PubMed  Article  CAS  Google Scholar 

  62. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007 Apr; 32(4): 765–72

    PubMed  Article  CAS  Google Scholar 

  63. Baptista T, Sandia I, Lacruz A, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007 Mar; 22(2): 69–76

    PubMed  Article  Google Scholar 

  64. Baptista T, Martinez M, Lacruz A, et al. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schizophr Res 2007 Jan; 89(1–3): 350–2

    PubMed  Article  Google Scholar 

  65. Carrizo E, Fernandez V, Quintero J, et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 2008 Aug; 103(1–3): 83–93

    PubMed  Article  Google Scholar 

  66. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005 May 13; 96(9): 939–49

    PubMed  Article  CAS  Google Scholar 

  67. Chan JC, Tong PC, Critchley JA. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk. Semin Vasc Med 2002 Feb; 2(1): 45–57

    PubMed  Article  Google Scholar 

  68. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008 Apr; 10(2): 156–64

    PubMed  Article  CAS  Google Scholar 

  69. American Diabetes Association. Executive summary: standards of medical care in diabetes, 2008. Diabetes Care 2008 Jan; 31Suppl. 1: S5–11

    Google Scholar 

  70. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment [online]. Available from URL: http://www.diabetes.com.au/pdf/obesity_report.pdf [Accessed 2009 Jan 10]

  71. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [online]. Available from URL: http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf [Accessed 2009 Jan 10]

  72. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 2007 Jun; 30(6): 1647–52

    PubMed  Article  Google Scholar 

  73. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001 May 16; 285(19): 2486–97

  74. Meisinger C, Doring A, Thorand B, et al. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr 2006 Sep; 84(3): 483–9

    PubMed  CAS  Google Scholar 

  75. World Health Organ. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Tech Rep Ser 2000; 894: i–253

    Google Scholar 

  76. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998 Jan; 22(1): 39–47

    PubMed  Article  CAS  Google Scholar 

  77. Nguyen TT, Adair LS, He K, et al. Optimal cutoff values for overweight: using body mass index to predict incidence of hypertension in 18- to 65-year-old Chinese adults. J Nutr 2008 Jul; 138(7): 1377–82

    PubMed  Google Scholar 

  78. Colin BA, Adair LS, Popkin BM. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002 Feb 15; 155(4): 346–53

    Article  Google Scholar 

  79. Mansour AA, Al-Hassan AA, Al-Jazairi MI. Cut-off values for waist circumference in rural Iraqi adults for the diagnosis of metabolic syndrome. Rural Remote Health 2007 Oct; 7(4): 765

    PubMed  CAS  Google Scholar 

  80. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004 May; 27(5): 1182–6

    PubMed  Article  Google Scholar 

  81. National Center for Health Statistics. 2000 CDC growth charts: United States [online]. Available from URL: http://www.cdc.gov/GrowthCharts/ [Accessed 2009 Jan 10]

  82. Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004 Aug; 114(2): e198–205

    PubMed  Article  Google Scholar 

  83. Ng VW, Kong AP, Choi KC, et al. BMI and waist circumference in predicting cardiovascular risk factor clustering in Chinese adolescents. Obesity (Silver Spring) 2007 Feb; 15(2): 494–503

    Article  Google Scholar 

  84. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007 Jul 10; 116(2): 151–7

    PubMed  Article  CAS  Google Scholar 

  85. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007 Feb; 30(2): 228–33

    PubMed  Article  CAS  Google Scholar 

  86. Su Y, Liu XM, Sun YM, et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 2008 Jun; 62(6): 877–82

    PubMed  Article  CAS  Google Scholar 

  87. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 Jan; 27Suppl. 1: S5–10

    Google Scholar 

  88. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism 2006 Apr; 55(4): 434–8

    PubMed  Article  CAS  Google Scholar 

  89. Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone 2007; 8(2): 10–8

    PubMed  Article  Google Scholar 

  90. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007 Apr; 68(4): 533–41

    PubMed  Article  CAS  Google Scholar 

  91. Dixon JB, O’Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m2. Int J Obes Relat Metab Disord 2001 Jun; 25(6): 793–7

    PubMed  Article  CAS  Google Scholar 

  92. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005 Jun; 25(3): 255–8

    PubMed  Article  CAS  Google Scholar 

  93. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23

    PubMed  Article  CAS  Google Scholar 

  94. Strack T. Metformin: a review. Drugs Today (Barc) 2008 Apr; 44(4): 303–14

    Article  CAS  Google Scholar 

  95. Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmacother 2007 Jul; 41(7): 1174–80

    PubMed  Article  CAS  Google Scholar 

  96. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 2007 Mar; 6(2): 191–8

    PubMed  Article  CAS  Google Scholar 

  97. Citrome L, Vreeland B. Schizophrenia, obesity, and anti-psychotic medications: what can we do? Postgrad Med 2008 Jul; 120(2): 18–33

    PubMed  Article  Google Scholar 

  98. National Heart Lung and Blood Institute, National Institute of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf [Accessed 2009 Jan 10]

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, 142 Minnesota Drive, Stephenville, Newfoundland, A2N 2V6, Canada

    Mehrul Hasnain

  2. Psychiatry and Medicine Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA

    W. Victor R. Vieweg

  3. Departments of Psychiatry and Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia, USA

    W. Victor R. Vieweg

  4. Medicine Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA

    Sonja K. Fredrickson

Authors
  1. Mehrul Hasnain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Victor R. Vieweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja K. Fredrickson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehrul Hasnain.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hasnain, M., Vieweg, W.V.R. & Fredrickson, S.K. Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation. CNS Drugs 24, 193–206 (2010). https://doi.org/10.2165/11530130-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11530130-000000000-00000

Keywords

  • Metformin
  • Waist Circumference
  • Clozapine
  • Risperidone
  • Olanzapine